Skip to main content
. 2022 May 17;14(10):2468. doi: 10.3390/cancers14102468

Table A4.

Demographic and disease characteristics on the index date a in the lapatinib cohort b stratified by prior pertuzumab use.

Pertuzumab Naive
(n = 13)
Pertuzumab-Experienced (n = 51) Overall
(n = 64)
2013–2014
(n = 11)
2015–2016
(n = 16)
2017–2018
(n = 16)
2019
(n = 8)
p-Value
Median age, years (IQR) 63 (59–78) 58 (54–68) 63 (53–70) 62 (54–69) 62 (57–67) 0.897 62 (54–69)
Metastatic status, n (%) 0.323
De novo 6 (46) ≤5 (<46) ≤5 (<32) 9 (56) 6 (75) 33 (52)
Recurrent 7 (54) 8 (73) 7 (44) 7 (44) ≤5 (<63) 31 (48)
Median BMI, kg/m2 (IQR) 25 (22–33) 26 (24–28) 30 (26–31) 26 (24–31) 24 (22–27) 0.243 27 (23–31)
BMI categorization, n (%) 0.533
Underweight (18.5 kg/m2) ≤5 (<39) ≤5 (<46) 0 0 0 ≤5 (<8)
Normal (19.5–24.9 kg/m2) 6 (46) ≤5 (<46) ≤5 (<32) 7 (44) ≤5 (<63) 24 (39)
Overweight (25.0–29.9 kg/m2) ≤5 (<39) ≤5 (<46) ≤5 (<32) ≤5 (<32) ≤5 (<63) 17 (28)
Obese (≥30 kg/m2) ≤5 (<39) ≤5 (<46) 7 (50) ≤5 (<32) ≤5 (<63) 18 (30)
Unknown 0 ≤5 (<46) ≤5 (<32) 0 0 ≤5 (<8)
Hormone receptor status, n (%) 0.495
Positive 7 (54) 8 (73) 13 (81) 12 (75) ≤5 (<63) 44 (69)
Negative ≤5 (<39) ≤5 (<46) ≤5 (<32) ≤5 (<32) ≤5 (<63) 19 (30)
Unknown ≤5 (<39) 0 0 0 0 ≤5 (<8)
Practice setting 0.028
Academic ≤5 (<39) 0 0 0 ≤5 (<63) ≤5 (<8)
Community-based 12 (92) 11 (100) 16 (100) 16 (100) 6 (75) 61 (95)
Median number of metastatic sites, n (IQR) 2 (1–3) 3 (3–4) 4 (3–5) 3 (2–5) 4 (1–5) 0.161 3 (2–5)
Metastatic site, n (%)
Bone 8 (62) 8 (73) 12 (75) 12 (75) ≤5 (<63) 0.905 45 (70)
Visceral 7 (54) 7 (64) 14 (88) 11 (69) ≤5 (<63) 0.348 44 (69)
Brain ≤5 (<39) ≤5 (<46) 10 (62) 8 (50) ≤5 (<63) 0.790 32 (50)
Liver ≤5 (<39) ≤5 (<46) 10 (62) 8 (50) ≤5 (<63) 0.139 29 (45)
Distant lymph node ≤5 (<39) ≤5 (<46) 6 (38) 9 (56) ≤5 (<63) 0.147 27 (42)
Lung 6 (46) ≤5 (<46) 8 (50) ≤5 (<32) ≤5 (<63) 0.873 27 (42)
Non-brain CNS 0 ≤5 (<46) 0 ≤5 (<32) 0 0.176 ≤5 (<8)
Other 0 ≤5 (<46) 0 ≤5 (<32) ≤5 (<63) 0.108 ≤5 (<8)
Prior treatments, n (%)
One prior treatment line 13 (100) 11 (100) 16 (100) 16 (100) 8 (100) NA 64 (100)
HER2-targeted treatments 13 (100) 11 (100) 16 (100) 16 (100) 8 (100) NA 64 (100)
Pertuzumab 0 11 (100) 16 (100) 16 (100) 8 (100) NA 51 (80)
Trastuzumab 13 (100) 11 (100) 16 (100) 16 (100) 8 (100) NA 64 (100)
T-DM1 0 ≤5 (<46) 0 0 0 0.297 ≤5 (<8)
Time from mBC diagnosis to lapatinib initiation, months
Median (IQR) 11 (7–16) 8 (7–17) 14 (11–19) 17 (13–23) 25 (15–29) 0.026 14 (9–20)
Mean (SD) 12 (7) 11 (7) 16 (9) 18 (8) 24 (13) 0.026 16 (9)
Index year, n (%) NA
2013–2014 6 (46) 11 (100) 0 0 0 17 (27)
2015–2016 ≤5 (<39) 0 16 (100) 0 0 18 (28)
2017–2018 ≤5 (<39) 0 0 16 (100) 0 19 (30)
2019 ≤5 (<39) 0 0 0 8 (100) 10 (16)

a Date on or prior to 31 December 2019, when treatment with lapatinib was initiated. b Patients who received 2L lapatinib. 2L = second-line; BMI = body mass index; CNS = central nervous system; DLN = distant lymph node; HER2 = human epidermal growth factor receptor 2; IQR = interquartile range; mBC = metastatic breast cancer; SD = standard deviation; T-DM1 = trastuzumab emtansine.